Early Proteomic and Metabolomic Signatures in Diabetes Associated with Progression to Diabetic Retinopathy Over 1–2 Years - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Initial Proteomic and Metabolomic Indicators in Diabetes Linked to the Development of Diabetic Retinopathy Within 1–2 Years

  • By

  • Zhao, Jing

  • Cao, Yitao

  • Chai, Zhi

  • Xie, Hanghang

  • Gu, Dandan

  • Yanchun, Zhang

  • Dongling, Niu

  • Liu, Hongli

  • Lei, Ting

  • May 29, 2026

Share

Clinical Scorecard: Initial Proteomic and Metabolomic Indicators in Diabetes Linked to the Development of Diabetic Retinopathy Within 1–2 Years

At a Glance

CategoryDetail
Condition
Key MechanismsRemove or provide source.
Target Population
Care Setting

Key Highlights

    Guideline-Based Recommendations

    Diagnosis

      Management

        Monitoring & Follow-up

          Risks

            Patient & Prescribing Data

            Remove speculative language.

            Clinical Best Practices

              Related Resources & Content

                Original Source(s)

                Early Proteomic and Metabolomic Signatures in Diabetes Associated with Progression to Diabetic Retinopathy Over 1–2 Years

                • by Zhao, Jing , Cao, Yitao , Chai, Zhi , Xie, Hanghang , Gu, Dandan , Yanchun, Zhang , Dongling, Niu , Liu, Hongli , Lei, Ting

                • May 29, 2026

                Related Content

                Semaglutide Linked to NAION Risk

                A retrospective database study found a low absolute incidence but higher relative hazard of ischemic optic neuropathy following semaglutide initiation.

                Retinal Age as Disease Biomarker

                Fundus-based AI screening can indicate “retinal age” of patients, as well as flag systemic disease risks, says new study

                • May 27, 2026

                • 3 min
                AI Tool May Cut Macular Edema Referrals

                An artificial intelligence–based optical coherence tomography pathway met noninferiority criteria for false-positive diabetic macular edema referrals and was associated with fewer referral decisions in a randomized clinical trial.